- Category: HBV Treatment
- Published on Tuesday, 08 April 2014 00:00
- Written by HIVandHepatitis.com
The European Association for the Study of the Liver's International Liver Congress (EASL 2014) takes place April 9-13 at the ExCel Centre in London. The annual conference is one of the key annual scientific meetings covering viral hepatitis and its complications. Also on Thursday, the World Health Organization (WHO) will release new global guidelines for hepatitis C.
With next-generation direct-acting antivirals exiting the development pipeline or in the final stages of testing, new treatments for hepatitis C will be a key theme of the meeting, in particular long-awaited interferon-free regimens. New data will be presented on several approved or Phase 3 drugs -- many with cure rates in the 90% to 100% range -- including:
- Gilead Sciences' sofosbuvir (Sovaldi) plus ledipasvir coformulation used alone or with ribavirin or a third DAA.
- Janssen's protease inhibitor simeprevir (Olysio) in interferon-free regimens.
- AbbVie's "3D" combination containing ABT-450, ABT-333, and ABT-267.
- Bristol-Myers Squibb's daclatasvir and asunaprevir.
- Merck's MK-5172 and MK-8742.
- Boehringer Ingelheim's faldaprevir.
Research is moving so fast that EASL hepatitis C treatment guidelines released last year are already out of date. EASL is expected to go the way of the American Association for the Study of Liver Disease (AASLD) which, along with the Infectious Diseases Society of America and the International Antiviral Society-USA, recently launched a website (HCVguidelines.org) featuring hepatitis C treatment guidance that can be quickly updated as new data become available.
Other topics to be covered at the EASL conference include hepatitis B and C epidemiology and public health, hepatitis B treatment, fatty liver disease and related metabolic conditions, non-invasive assessment of liver damage, management of cirrhosis and liver cancer, and advances in liver transplantation.
A major theme in the public health realm will be cost and access issues for new hepatitis C treatments in Europe and worldwide. Representatives from groups working on treatment access, including Médecins Sans Frontières and the World Hepatitis Alliance, will speak at the WHO press conference on Thursday morning.
Look for breaking news coverage from HIVandHepatitis.com and our partners at Aidsmap starting on Thursday at www.HIVandHepatitis.com and via @HIVandHepatitis on Twitter. Abstracts and other information are available on the conference web site.
EASL International Liver Congress. www.ilc-congress.eu/2014/ilc-2014.html.